Results 11 to 20 of about 125,474 (196)
Journal of Mazandaran University of Medical Sciences, 2005 Background and purpose: Chronic anovulation is a common cause of infertility in women. Most women with chronic anoulation have irregular menstural cycles and normal serum FSH concentration s(WHO-type 2).finding out influential factors on ovarian ...
T. Madani +3 more
doaj +1 more source
Tamoxifen and the uterus [PDF]
BMJ, 1994 The effects of tamoxifen on the endometrium have caused concern since the late 1980s,1,2 and clear evidence of endometrial changes has now emerged from three studies in postmenopausal women - one case-control study of breast cancer3 and two randomised controlled trials, one in women with early breast cancer4 and one in healthy women with a family ...
P, Neven +4 more
openaire +5 more sources
Microarray analysis of tamoxifen resistance in breast cancer. [PDF]
, 2009 PhDTamoxifen remains a widely used hormone therapy for pre and postmenopausal women with hormone receptor positive breast cancer in both adjuvant and metastatic disease settings. Resistance to this well tolerated and cost-effective drug limits its use.
Moss, Charlotte
core +4 more sources
Molecular gene expression and genome wide profiling in tamoxifen-resistant breast cancer. [PDF]
, 2010 PhDOestrogen receptor positive (ER+) breast cancers (BC) are heterogeneous in both their clinical behaviour and response to therapy. The ER and Progesterone (PgR) are currently the best predictors of response to the anti-oestrogen tamoxifen, yet up to 40%
Yeoh, Chit Cheng
core +4 more sources
Italian randomized trial among womenwith histerectomy: tamoxifen and hormone-dependent breast cancer in hight-risk women [PDF]
, 2003 Tamoxifen improves outcome in women with breast cancer and reduces the incidence of estrogen receptor-positive (ER+) breast tumors in prevention trials. Tamoxifen use is associated with an increased risk of potentially serious adverse events, principally
MAISSONEUVE P +5 more
core +1 more source
PLoS ONE, 2014 Tamoxifen provided a successful treatment for ER-positive breast cancer for many years. However, most breast tumors develop tamoxifen resistance and are eventually refractory to tamoxifen therapy.
Li Yin +4 more
doaj +1 more source
BMC Cancer, 2010 Background The cytochrome P450 (CYP) enzymes 2C19, 2D6, and 3A5 are responsible for converting the selective estrogen receptor modulator (SERM), tamoxifen to its active metabolites 4-hydroxy-tamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam,
Lundgren Steinar +7 more
doaj +1 more source
Scientific Reports, 2020 Tamoxifen resistance is emerging as a big challenge in endocrine therapy of luminal A breast cancer patients. In this study, we aimed to determine the molecular changes of PI3K/AKT/PTEN signaling pathway during tamoxifen-resistance development using ...
Lama Hamadneh +3 more
doaj +1 more source
Combination treatment of tamoxifen with risperidone in breast cancer.
PLoS ONE, 2014 Tamoxifen has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre- and post-menopause women. Tamoxifen exerts its cytotoxic effect primarily through
Wei-Lan Yeh +3 more
doaj +1 more source
NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer
Cells, 2021 Endocrine therapy is used to treat estrogen receptor (ER)-positive breast cancer. Tamoxifen is effective against this cancer subtype. Nonetheless, approximately 30% of patients treated with tamoxifen acquire resistance, resulting in therapeutic ...
Yu Cheon Kim +3 more
doaj +1 more source